Kidder Stephen W Sells 2,263 Shares of Johnson & Johnson $JNJ

Kidder Stephen W cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,180 shares of the company’s stock after selling 2,263 shares during the quarter. Johnson & Johnson accounts for about 3.1% of Kidder Stephen W’s holdings, making the stock its 12th biggest holding. Kidder Stephen W’s holdings in Johnson & Johnson were worth $10,414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in JNJ. Nuveen LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $1,369,188,000. Bank of New York Mellon Corp lifted its holdings in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after acquiring an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $401,420,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a report on Friday, October 3rd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Bank of America lifted their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $191.41.

Johnson & Johnson Stock Up 0.7%

Shares of Johnson & Johnson stock opened at $190.97 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $178.01 and its two-hundred day simple moving average is $163.56. The company has a market cap of $459.92 billion, a P/E ratio of 20.42, a PEG ratio of 2.42 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $192.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.